ABSTRACT

The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. The GLP-1 receptor agonist or the controlled-release formulation thereof according to the present invention has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa.

Figure 4